William Aird/X
Sep 17, 2025, 10:54
Mitapivat Boosts ATP in Red Cells: Dr. William Aird on New Hope for Hemolytic Disorder
William Aird, Professor of Medicine at Harvard Medical School, posted on X:
”POWERING UP RBCs
Mitapivat is an oral allosteric activator of pyruvate kinase → ↑ glycolytic ATP.
FDA-approved for PK deficiency anemia; in trials for sickle cell disease and thalassemia.
More ATP = healthier, longer-lived red cells across hemolytic disorders.”
Stay updated with Hemostasis Today.
-
Aug 19, 2026, 19:09Gregory Lip: PFO Closure in Younger Patients With Cryptogenic Stroke
-
Aug 19, 2026, 18:51Filippo Crea: AF and Alzheimer’s Disease – Does the Anticoagulant Choice Matter for the Brain?
-
Aug 19, 2026, 18:42Alan Nurden: How Procoagulant Platelets Relate to Microparticle Release?
-
Aug 19, 2026, 18:25Ivan Centeno Sáenz: FeNO and Biomass Smoke-Associated Chronic Obstructive Pulmonary Disease
-
Aug 19, 2026, 18:10Ahmad Hazri Mohamed Aris: Strengthening Hemophilia Care and Access to Treatment in Fiji
-
Aug 19, 2026, 17:58Paulomi Ghosh: Delighted to Deliver a Talk on Hemostasis and Hemorrhage Control
-
Aug 19, 2026, 17:34Ryan O’Keefe: Clopidogrel Non-Responders and the Risk of Stent Thrombosis
-
Aug 19, 2026, 17:10Mavis Agnes Kisakye: Raising Awareness and Supporting Patients With Bleeding Disorders
-
Aug 19, 2026, 17:02Daniel Barsanow: ETHIZIA vs TachoSil for Hemostasis During Open Liver Surgery